More intelligence articles

It’s not the end of the world, is it?

Industry change isn’t always gradual – it can be apocalyptic

Is anybody listening?

Chris Ross explores how pharma can – indeed must – end its long history of anti-social behaviour

The trials and tribulations of rare opportunities

Those hoping to follow where Humira, Soliris and Fabrazyme led should be prepared for clinical development to be complex

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

This year's list contains no cancer drugs

The UK’s new medicines pricing deal – opportunities and risks for pharma

What pharma needs to know about the new five-year deal

Pharmaceutical social media after Cambridge Analytica

As MPs call for the regulation of social media companies, what are the ethical and compliance implications for the pharmaceutical industry?

Gene therapy market access Q&A

Jesper Jorgensen, Health Economics and Market Access Manager, Cell and Gene Therapy Catapult gives his personal view on how to get the new therapies to patients

Bluebird: on a mission to ‘recode’ the DNA of healthcare

Europe is the test ground for the gene therapy pioneer’s outcomes-based model, which could set the standard for the emerging sector

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality

How pharma is progressing their commitment in patient engagement

Breaking Bad

Six behaviours separate the good brand teams from the bad

The first, my last, my everything

The inescapable rise of patient-centricity

Vertex: a vision of treating all CF patients worldwide draws closer

Its high prices are controversial, but Vertex also embodies the best of biopharma drug development

Galderma launches Rosacea awareness campaign

Campaign comes on the back of Rosacea Awareness Month

The Orkambi row explained

Q&A and timeline